Circulating aldosterone and mortality in female nursing home residents

Experimental Gerontology

Volumn 48, Issue 3, 2013, Pages 313-318

  Tomaschitz, Andreas ^a   Pilz, Stefan ^a,b   Pieske, Burkert ^a   Ritz, Eberhard ^c   März, Winfried ^a,d,e   Meinitzer, Andreas ^a   Dobnig, Harald ^a   Amrein, Karin ^a   Kienreich, Katharina ^a   Verheyen, Nicolas ^a   Kraigher Krainer, Elisabeth ^a   Drechsler, Christiane ^f   Colantonio, Caterina ^a   Wagner, Doris ^a   Fahrleitner Pammer, Astrid ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e SYNLAB ACADEMY   (Germany)

^f UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

Aldosterone; Elderly female individuals; Heart failure; Mortality; Nursing home residents

Indexed keywords

ALDOSTERONE; HEMOGLOBIN A1C;

AGED; ALDOSTERONE BLOOD LEVEL; ARTICLE; AUSTRIA; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HAZARD RATIO; HEART FAILURE; HEMOGLOBIN BLOOD LEVEL; HORMONE DETERMINATION; HORMONE RESPONSE; HUMAN; MEDICAL EXAMINATION; MORTALITY; NURSING HOME PATIENT; OBSERVATIONAL STUDY; POPULATION RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT;

AGED; AGED, 80 AND OVER; ALDOSTERONE; AUSTRIA; BIOLOGICAL MARKERS; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HEART FAILURE; HEMOGLOBIN A, GLYCOSYLATED; HOMES FOR THE AGED; HUMANS; MORTALITY; NURSING HOMES; PROSPECTIVE STUDIES;

EID: 84873291048     PISSN: 05315565     EISSN: 18736815     Source Type: Journal    
DOI: 10.1016/j.exger.2013.01.004     Document Type: Article

References (37)

1. Bertocchio J.P., Warnock D.G., Jaisser F. Mineralocorticoid receptor activation and blockade: an emerging paradigm in chronic kidney disease. Kidney Int. 2011, 79:1051-1060.
2. Bomback A.S., Klemmer P.J. The incidence and implications of aldosterone breakthrough. Nat. Clin. Pract. Nephrol. 2007, 3:486-492.
3. Catena C., Lapenna R., Baroselli S., Nadalini E., Colussi G., Novello M., Favret G., Melis A., Cavarape A., Sechi L.A. Insulin sensitivity in patients with primary aldosteronism: a follow-up study. J. Clin. Endocrinol. Metab. 2006, 91:3457-3463.
4. Dobnig H., Piswanger-Sölkner J.C., Roth M., Obermayer-Pietsch B., Tiran A., Strele A., Maier E., Maritschnegg P., Sieberer C., Fahrleitner-Pammer A. Type 2 diabetes mellitus in nursing home patients: effects on bone turnover, bone mass, and fracture risk. J. Clin. Endocrinol. Metab. 2006, 91:3355-3363.
5. Dobnig H., Piswanger-Sölkner J.C., Obermayer-Pietsch B., Tiran A., Strele A., Maier E., Maritschnegg P., Riedmüller G., Brueck C., Fahrleitner-Pammer A. Hip and nonvertebral fracture prediction in nursing home patients: role of bone ultrasound and bone marker measurements. J. Clin. Endocrinol. Metab. 2007, 92:1678-1686.
6. Edelmann F., Tomaschitz A., Wachter R., Gelbrich G., Knoke M., Dungen H.D., Pilz S., Binder L., Stahrenberg R., Schmidt A., März W., Pieske B. Serum aldosterone and its relationship to left ventricular structure and geometry in patients with preserved left ventricular ejection fraction. Eur. Heart J. 2012, 33(2):203-212.
7. Epstein M. Aldosterone blockade: an emerging strategy for abrogating progressive renal disease. Am. J. Med. 2006, 119:912-919.
8. Funder J. Minireview: aldosterone and mineralocorticoid receptors: past, present, and future. Endocrinology 2010, 151(11):5098-5102.
9. Ivanes F., Susen S., Mouquet F., Pigny P., Cuilleret F., Sautiere K., Collet J.P., Beygui F., Hennache B., Ennezat P.V., Juthier F., Richard F., Dallongeville J., Hillaert M.A., Doevendans P.A., Jude B., Bertrand M., Montalescot G., Van Belle E. Aldosterone, mortality, and acute ischaemic events in coronary artery disease patients outside the setting of acute myocardial infarction or heart failure. Eur. Heart J. 2012, 33:191-202.
10. Jain G., Campbell R.C., Warnock D.G. Mineralocorticoid receptor blockers and chronic kidney disease. Clin. J. Am. Soc. Nephrol. 2009, 4:1685-1691.
11. Kanashiro-Takeuchi R.M., Heidecker B., Lamirault G., Dharamsi J.W., Hare J.M. Sex-specific impact of aldosterone receptor antagonism on ventricular remodeling and gene expression after myocardial infarction. Clin. Transl. Sci. 2009, 2:134-142.
12. Levey A.S., Stevens L.A., Schmid C.H., Zhang Y.L., Castro A.F., Feldman H.I., Kusek J.W., Eggers P., Van Lente F., Greene T., Coresh J. A new equation to estimate glomerular filtration rate. Ann. Intern. Med. 2009, 150:604-612. CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration).
13. Maron B.A., Leopold J.A. Aldosterone receptor antagonists: effective but often forgotten. Circulation 2010, 121:934-939.
14. Matsui H., Ando K., Kawarazaki H., Nagae A., Fujita M., Shimosawa T., Nagase M., Fujita T. Salt excess causes left ventricular diastolic dysfunction in rats with metabolic disorder. Hypertension 2008, 52:287-294.
15. Mizuno Y., Yoshimura M., Yasue H., Sakamoto T., Ogawa H., Kugiyama K., Harada E., Nakayama M., Nakamura S., Ito T., Shimasaki Y., Saito Y., Nakao K. Aldosterone production is activated in failing ventricle in humans. Circulation 2001, 103:72-77.
16. Muzzarelli S., Maeder M.T., Toggweiler S., Rickli H., Nietlispach F., Julius B., Burkard T., Pfisterer M.E., Brunner-La Rocca H.P., TIME-CHF Investigators Frequency and predictors of hyperkalemia in patients ≥60years of age with heart failure undergoing intense medical therapy. Am. J. Cardiol. 2012, 109:693-698.
17. Nagase M., Fujita T. Mineralocorticoid receptor activation in obesity hypertension. Hypertens. Res. 2009, 32:649-657.
18. Nagase M., Matsui H., Shibata S., Gotoda T., Fujita T. Salt-induced nephropathy in obese spontaneously hypertensive rats via paradoxical activation of the mineralocorticoid receptor: role of oxidative stress. Hypertension 2007, 50:877-883.
19. Nguyen Dinh Cat A., Griol-Charhbili V., Loufrani L., Labat C., Benjamin L., Farman N., Lacolley P., Henrion D., Jaisser F. The endothelial mineralocorticoid receptor regulates vasoconstrictor tone and blood pressure. FASEB J. 2010, 24:2454-2463.
20. Pitt B., Zannad F., Remme W.J., Cody R., Castaigne A., Perez A., Palensky J., Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med. 1999, 341:709-717.
21. Pitt B., Remme W., Zannad F., Neaton J., Martinez F., Roniker B., Bittman R., Hurley S., Kleiman J., Gatlin M. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 2003, 348:1309-1321.
22. Roongsritong C., Sutthiwan P., Bradley J., Simoni J., Power S., Meyerrose G.E. Spironolactone improves diastolic function in the elderly. Clin. Cardiol. 2005, 28:484-487.
23. Shibata S., Nagase M., Yoshida S., Kawarazaki W., Kurihara H., Tanaka H., Miyoshi J., Takai Y., Fujita T. Modification of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease. Nat. Med. 2008, 14(1370):6.
24. Sowers J.R., Whaley-Connell A., Epstein M. Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension. Ann. Intern. Med. 2009, 150:776-783.
25. Swedberg K., Eneroth P., Kjekshus J., Wilhelmsen L. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation 1990, 82:1730-1736.
26. Tomaschitz A., März W., Pilz S., Ritz E., Scharnagl H., Renner W., Boehm B.O., Fahrleitner-Pammer A., Weihrauch G., Dobnig H. Aldosterone/renin ratio determines peripheral and central blood pressure values over a broad range. J. Am. Coll. Cardiol. 2009, 55:2171-2180.
27. Tomaschitz A., Pilz S., Ritz E., Meinitzer A., Boehm B.O., März W. Plasma aldosterone levels are associated with increased cardiovascular mortality: the Ludwigshafen Risk and Cardiovascular Health (LURIC) study. Eur. Heart J. 2010, 31:1237-1247.
28. Tomaschitz A., Pilz S., Ritz E., Obermayer-Pietsch B., Pieber T.R. Aldosterone and arterial hypertension. Nat. Rev. Endocrinol. 2010, 6:83-93.
29. Tomaschitz A., Pilz S., Ritz E., Grammer T., Drechsler C., Boehm B.O., März W. Association of plasma aldosterone with cardiovascular mortality in patients with low estimated GFR: the Ludwigshafen Risk and Cardiovascular Health (LURIC) Study. Am. J. Kidney Dis. 2011, 57:403-414.
30. Tomaschitz A., Pilz S., März W. Arterial hypertension and cardiovascular disease - absolute aldosterone excess is the tip of the iceberg. J. Lab. Med. 2011, 35(3):147-152.
31. Tomaschitz A., Ritz E., Pieske B., Fahrleitner-Pammer A., Kienreich K., Horina J.H., Drechsler C., März W., Ofner M., Pieber T.R., Pilz S. Aldosterone and parathyroid hormone - a precarious couple for cardiovascular disease. Cardiovasc. Res. 2012, 1;94(1):10-19.
32. Tsunoda K., Abe K., Goto T., Yasujima M., Sato M., Omata K., Seino M., Yoshinaga K. Effect of age on the renin-angiotensin-aldosterone system in normal subjects: simultaneous measurement of active and inactive renin, rennin substrate, and aldosterone in plasma. J. Clin. Endocrinol. Metab. 1986, 62:384-389.
33. Vasan R.S., Evans J.C., Larson M.G., Wilson P.W., Meigs J.B., Rifai N., Benjamin E.J., Levy D. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N. Engl. J. Med. 2004, 351:33-41.
34. Wada T., Kenmochi H., Miyashita Y., Sasaki M., Ojima M., Sasahara M., Koya D., Tsuneki H., Sasaoka T. Spironolactone improves glucose and lipid metabolism by ameliorating hepatic steatosis and inflammation and suppressing enhanced gluconeogenesis induced by high-fat and high-fructose diet. Endocrinology 2010, 151:2040-2049.
35. Whaley-Connell A., Johnson M.S., Sowers J.R. Aldosterone: role in the cardiometabolic syndrome and resistant hypertension. Prog. Cardiovasc. Dis. 2010, 52:401-409.
36. Xue C., Siragy H.M. Local renal aldosterone system and its regulation by salt, diabetes, and angiotensin II type 1 receptor. Hypertension 2005, 46:584-590.
37. Zannad F., McMurray J.J., Krum H., van Veldhuisen D.J., Swedberg K., Shi H., Vincent J., Pocock S.J., Pitt B. Eplerenone in patients with systolic heart failure and mild symptoms. N. Engl. J. Med. 2011, 364(1):11-21.